Vivos Therapeutics, Inc.

VVOS Nasdaq SEC CIK 1716166
Follow Vivos Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $6.4M −5.4% vs same quarter last year
Net income −$1.9M +64% vs same quarter last year
EPS, diluted −$0.07 +85.7% vs same quarter last year
Operating cash flow −$3.2M +23.7% vs same quarter last year
Revenue by quarter
$3.7M
$3M
$3.8M
$6.8M
$3.8M
$5.1M
$5.2M
$6.4M
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income8 fiscal years
  • Revenue
  • Net income
−$40M−$20M$0$20MFY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearRevenueNet income
FY25$17.4M−$21.2M
FY24$15M−$11.1M
FY23$13.8M−$13.6M
FY22$16M−$23.8M
FY21$16.9M−$20.3M
FY20$13.1M−$12.1M
FY19$11.4M−$10.8M
FY18--
MarginsShare of revenue
  • Gross margin
  • Operating margin
  • Net margin
−200%−100%0%100%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearGross marginOperating marginNet margin
FY2560.4%−114.1%−121.7%
FY2460%−74.3%−74.1%
FY2359.9%−125.3%−98.4%
FY2262.5%−156.2%−148.8%
FY2174.6%−120.7%−120.2%
FY2079.7%−92.1%−92.3%
FY1976%−92.8%−94.4%
FY18---
Free cash flowOperating cash flow minus capital expenditure
−$30M−$20M−$10M$0FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearFree cash flow
FY25−$17.6M
FY24−$13.3M
FY23−$12.7M
FY22−$20.5M
FY21−$18.1M
FY20−$5.8M
FY19−$5.5M
FY18-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Vivos Therapeutics
  • Healthcare median
−150%−100%−50%0%FY18FY19FY20FY21FY22FY23FY24FY25
Show the numbers
YearVivos TherapeuticsHealthcare median
FY25−121.7%−30.6%
FY24−74.1%−47%
FY23−98.4%−58%
FY22−148.8%−80.4%
FY21−120.2%−71.9%
FY20−92.3%−62.2%
FY19−94.4%−46.3%
FY18-−49.6%